© Copyright 2016 The KINDReD ASSOCIATION. All rights reserved.
HOME MEMBERS NEGLECTED PARASITIC DISEASES DRUG DEVELOPMENT PIPELINE NEWS & PUBLICATIONS JOIN US CONTACT
Made in France

WELCOME

to The KINDReD Association website. The mission of “The KINDReD ASSOCIATION” is to promote research and development of new drug molecules against Neglected Tropical diseases (NTDs). The KINDReD Association was created to continue the major progress established by the KINDReD consortium funded under the EU 7the Framework Programme (N°602773).  The KINDReD consortium has made phenomenal progress in the discovery of new targets and therapeutic molecules in the fight against NTDs. New drug candidates have been developed and are currently in preclinical testing. The role of the KINDReD Association is to ensure that these molecules continue through preclinical and clinical development, gaining regulatory approval, with the ultimate aim of providing a wide choice of cost- effective and safe drugs to combat NTDs. The KINDReD ASSOCIATION, an independent, charitable body aims to promote a healthy portfolio of new clinical candidates, as the well- recognised high attrition rates in clinical trials means that many drugs may succumb to safety and efficacy issues. The Association will initially sponsor the molecules resulting from the European Community’s Seventh Framework Programme under grant agreement No.602773 (Project KINDReD), which reaches term in August 2016. However, it is open to receive other advanced molecules from any source, and also against other neglected infectious diseases, on the understanding that there is absolute adherence to open source drug discovery with full freedom to operate accompanying any eventual intellectual property rights.

Drugs againsts neglected

parasitic diseases

The trypanosomatid diseases;  Leishmaniasis, Human African  trypanosomiasis and Chagas disease, continue to impart a heavy toll on  human health, affecting millions of  people worldwide, particularly those  living in the economically poorest  countries. The handful of treatments  available to control this enormous  heath burden is limited by serious  adverse effects, high costs, difficulties  in administration and the ever  advancing spectre of drug… 
MORE INFO
Together, we will win against  neglected infectious diseases.
Follow-us!
Join-Us HOME

WELCOME

to The KINDReD Association website. The mission of “The KINDReD ASSOCIATION” is to promote research and development of new drug molecules against Neglected Tropical diseases (NTDs). The KINDReD Association was created to continue the major progress established by the KINDReD consortium funded under the EU 7the Framework Programme (N°602773).  The KINDReD consortium has made phenomenal progress in the discovery of new targets and therapeutic molecules in the fight against NTDs. New drug candidates have been developed and are currently in preclinical testing. The role of the KINDReD Association is to ensure that these molecules continue through preclinical and clinical development, gaining regulatory approval, with the ultimate aim of providing a wide choice of cost- effective and safe drugs to combat NTDs. The KINDReD ASSOCIATION, an independent, charitable body aims to promote a healthy portfolio of new clinical candidates, as the well- recognised high attrition rates in clinical trials means that many drugs may succumb to safety and efficacy issues. The Association will initially sponsor the molecules resulting from the European Community’s Seventh Framework Programme under grant agreement No.602773 (Project KINDReD), which reaches term in August 2016. However, it is open to receive other advanced molecules from any source, and also against other neglected infectious diseases, on the understanding that there is absolute adherence to open source drug discovery with full freedom to operate accompanying any eventual intellectual property rights.
© Copyright 2016 The KINDReD ASSOCIATION. All rights reserved.
NAVIGATION MENU
Made in France

Drugs againsts neglected

parasitic diseases

The trypanosomatid diseases; Leishmaniasis,  Human African trypanosomiasis and Chagas  disease, continue to impart a heavy toll on  human health, affecting millions of people  worldwide, particularly those living in the  economically poorest countries. The handful of  treatments available to control this enormous  heath burden is limited by serious adverse  effects, high costs, difficulties in administration  and the ever advancing spectre of drug…
MORE INFO
Together, we will win against  neglected infectious diseases.
Follow-us!
Join-Us